In this tiresome up-every-day market, here are some relatively new stocks that continue to show verve. Of course, high-fliers in a richly-valued market are still...
1. BioCryst BioCryst Pharmaceuticals (NASDAQ:BCRX), in the biotech vaccine area, on Tuesday popped to 5.41, up 46 cents, or 9%, after reaching a midday high of 5.56, on 10.9...
1. Amyris (NASDAQ:AMRS) popped on Monday with good volume, gaining 81 cents, or 30%, to 3.49, after reaching a session high of 3.70, on 6.4 million shares traded. It broke out...
The often overlooked segment, the small-cap healthcare, has been outperforming this year. This is especially true as the S&P Small Cap 600 Health Care sector has gained 5.6% so...
The past week was busy for the biotech sector with quite a few data releases. Biogen (NASDAQ:BIIB) and Conatus (NASDAQ:CNAT) crash on study setbacks while the FDA refused to...
Amgen (NASDAQ:AMGN) , Cytokinetics, Inc. (NASDAQ:CYTK) and Servier announced that the enrollment for the second phase III study of omecamtiv mecarbil, a novel cardiac myosin...
For Immediate ReleaseChicago, IL –February 14, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
Market watchers still quibble over whether the equity market entered bear market territory or underwent a correction in year-end 2018. But there is little debate over the fate of...
Cytokinetics, Incorporated (NASDAQ:CYTK) has been struggling lately, but the selling pressure may be coming to an end soon. That is because CYTK recently saw a Hammer Chart...
Investors in Cytokinetics, Incorporated (NASDAQ:CYTK) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 15, 2017 $19...